Background: Anti-glucagon medications as amylin and its analogs are emerging antihyperglycemic agents which recently have gained attention. However, studies exploring cardiovascular effects of amylin have shown mixed outcomes. We aimed to assess the effects of amylin on cardiac performance in experimentally induced T2D in rats. Methods: 40 adult female Wistar Albino rats were allocated into 3 groups (control group, diabetic group and a group of diabetic rats treated with amylin). ECG as well as the in vitro responses to isoproterenol infusion by Langendorff's preparation were also assessed. Results: Median baseline peak developed tension (PT) and PT per left ventricular weight (PT/LV) were significantly lowered in the diabetic group compared to the control group. Both parameters in the amylin treated group were significantly increased compared to the diabetic group and approached the normal control values. As regards cardiac responses to isoproterenol infusion, maximal and delta changes of HR, PT and PT/LV were significantly decreased in the diabetic group compared to the control group. Maximal and recovery HR values as well as maximal PT and PT/LV became normalized in the amylin treated group. The diabetic group also showed significant prolongation of TPT, HRT and decrease of TGT, MFR/LV maximal responses to isoproterenol compared to control group. Those parameters were significantly improved in the amylin treated group and reached the control values. Conclusions: Amylin was able to impose partial improvement on cardiac chronotropic, inotropic functions and myocardial blood flow in diabetic state in response to beta adrenergic stimulation.